News | November 14, 2013

AngioScore Announces Preliminary Clinical Trial Results for World’s First Drug-Coated Scoring Balloon Catheter

balloon catheters cath lab drug-eluting clinical trials angioscore angiosculpt
November 14, 2013 — AngioScore, Inc., a developer of angioplasty catheters for use in the treatment of cardiovascular disease, announced detailed preliminary clinical trial results for the world’s first drug-coated scoring balloon catheter.
This first-in-human (FIH) trial of a novel drug-coated AngioSculpt PTCA (percutaneous transluminal coronary angioplasty) Scoring Balloon Catheter (PATENT-C) enrolled 61 patients with coronary in-stent restenosis (ISR) at five sites: four in Germany and one in Brazil. Bruno Scheller, M.D., professor of interventional cardiology, Saarland University Hospital, Homburg, Germany led the study.
The PATENT-C study was designed as a randomized controlled trial comparing the recently developed drug-coated AngioSculpt with the commercially available uncoated version of the AngioSculpt in patients presenting with significant restenosis in a previously implanted coronary bare-metal stent. Patients underwent follow-up quantitative coronary angiography (QCA) at six months to compare the rate of recurrent restenosis and late lumen loss (LLL) in both treatment arms. Additional study endpoints included the rate of major adverse cardiovascular events (MACE), clinically driven target lesion revascularization (TLR) and stent thrombosis for up to two years following the index procedure. An independent core laboratory at the Cardiovascular Research Foundation in New York analyzed all angiograms.
The six-month clinical and QCA results from PATENT-C were first presented at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2013) in San Francisco. Overall, the trial easily met the primary efficacy endpoint with an in-segment LLL of 0.14±0.4 mm and 0.47±0.51 mm for the drug-coated and uncoated AngioSculpt groups respectively (p<0.05). This was even more significant when the patients were evaluated according to the actual treatment received, with the drug-coated AngioSculpt group achieving an in-segment LLL of 0.07±0.24 mm (p < 0.01). These angiographic findings were paralleled by a marked reduction in adverse events, including clinically driven TLR, in the AngioSculpt-treated patients. 
“The six-month results of the PATENT-C Trial are impressive and appear to be among the best angiographic and clinical outcomes available to date for the emerging field of drug-coated balloons,” said Gary Gershony, M.D., co-founder and chief medical officer, AngioScore. “The development of a drug-coated AngioSculpt Scoring Balloon Catheter has the potential to become a disruptive new technology for the treatment of complex coronary and peripheral artery disease.”
AngioSculpt catheters have now been used in more than 300,000 procedures worldwide. 
The Drug-Coated AngioSculpt Scoring Balloon Catheter is an investigational device, limited by applicable law to investigational use and not available for sale.
For more information:

Related Content

Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init